" class="no-js "lang="en-US"> Kausik Ray - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
Kausik Ray

Kausik Ray

About Kausik Ray

President European Atherosclerosis Society 2021-2024

Current work : Leading the European Atherosclerosis Society FH Studies Collaboration including Asia Pacific, Africa, South America, Europe and the Middle East.

Leading the TOEGETHER study assessing the vascular health check data on 250 000 people.

Steering committee or Executive committee member on 8 RCTS and PI

Steering committee member of ADORE (DM Registry of 10 000 people in Asia) and TIGRIS (registry of 10 000 stable CAD patients)

Related Story

Industry News

 World-first Agreement Between Novartis and the NHS Enables Broad and Rapid Access to First-in-class Cholesterol-lowering Medicine Leqvio® ▼(inclisiran) | Pharmtech Focus

World-first Agreement Between Novartis and the NHS Enables Broad and Rapid Access to First-in-class Cholesterol-lowering Medicine Leqvio® ▼(inclisiran)

September 1 2021

Novartis has reached a commercial agreement with the NHS in England as part of a […]